Effect of MHSP65-TCL anti-melanoma vaccine on the activity of immunocytes
- VernacularTitle:MHSP65-TCL抗黑色素瘤疫苗对免疫细胞活性的影响
- Author:
Bohan DONG
1
;
Guangli DAI
;
Zhilin QI
;
Guang YANG
;
Jun L
;
Yao ZHANG
Author Information
1. 皖南医学院基础医学部
- Keywords:
tumor cell lysate;
melanoma;
anti-tumor immunotherapy;
immunocyte suppression
- From:
Journal of Southern Medical University
2013;(11):1673-1677
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect of MHSP65-TCL on melanoma and its effect on the activity of the immunocytes. Methods MHSP65-TCL was prepared by mixing MHSP65 with TCL derived from B16 melanoma cell lysate by repeated freezing and thawing. The MHSP65-TCL vaccine was administered in mice bearing B16 melanoma, and the changes in melanoma growth was observed. To investigate the influence of TCL in MHSP65-TCL on the activity of the immunocytes, we co-cultured TCL and mouse spleen cells in vitro, and analyzed CD69 expression on the cells, cell apoptosis, and levels of IL-10 and IFN-γin the cell culture supernatant. Results The MHSP65-TCL vaccine showed an anti-melanoma effect in the tumor-bearing mice. In the in vitro experiment, TCL in MHSP65-TCL strongly stimulated the activation of mouse spleen cells while causing apoptosis in some of the immunocytes and promoting cellular IL-10 secretion, but not IFN-γ. Conclusions MHSP65-TCL derived from B16 melanoma cells has an anti-melanoma effect mediated by the activation of immunocytes. TCL in MHSP65-TCL also has immunosuppressive effect on immunocytes possibly due to the presence of suppressive components in TCL, and identifying and eliminating these components may potentially improve the anti-tumor actovoty of MSHP65-TCL vaccine.